Prostate cancer decisions — 2022

The Board has remanded the case due to unclear findings regarding the Veteran's prostate cancer and his ability to work.

The Board denied service connection for kidney cancer and prostate cancer, finding that the conditions are not related to service or any service-connected disability.

The Board denied service connection for prostate cancer, squamous cell cancer (SCC), and a colostomy. The cancers are considered secondary to the Veteran's prostate cancer, which is not service-connected due to lack of evidence linking it to his service or exposure to tactical herbicides.

The Veteran's appeal for restoration of a 100 percent rating for prostate cancer and a higher rating for residuals of prostate cancer is denied. The Veteran's prostate cancer was found to be in remission, with predominant residual dysfunction being voiding dysfunction.

The Veteran's prostate cancer and erectile dysfunction have been granted service connection with effective dates of December 10, 2018 for the prostate cancer and May 10, 2019 for the erectile dysfunction. The Veteran is also entitled to SMC based on loss of use of a creative organ as of May 10, 2019.

The Veteran's prostate cancer, ischemic heart disease, diabetes mellitus, type II, and bilateral peripheral neuropathy were denied service connection as they are not related to his active military service.,Service connection for the Veteran's prostate cancer was reopened due to new evidence provided.

The Board granted a TDIU on an extraschedular basis, and the appellant is entitled to attorney fees in full amount of 20 percent of past-due benefits awarded.

The Veteran's prostate cancer residuals are rated at 40 percent beginning October 1, 2019. The decision grants a higher rating than the current 10 percent for his service-connected prostate cancer.

The Veteran's prostate cancer is presumed to have been caused by herbicide agent exposure during his service in Vietnam. Service connection for prostate cancer is granted.

The Veteran's claims for coronary artery disease, congestive heart failure, prostate cancer, and prostatitis have been dismissed due to the death of the appellant.

The Board denied the Veteran's claim for service connection for prostate cancer, finding that there was no evidence of exposure to herbicide agents during his service aboard the USS Kearsarge and thus the presumption of herbicide exposure is inapplicable. The Board also found that there was no competent evidence showing a diagnosis or etiology of prostate cancer during service.

The Veteran's prostate cancer is not service connected as it was not shown to be related to his military service, including exposure to contaminated water at Camp Lejeune.

The Veteran's residuals of prostate cancer, which required the use of more than four absorbent materials per day for urinary incontinence, are granted a 60 percent rating (excluding periods of 100 percent ratings).

The Board has granted service connection for prostate cancer due to exposure to herbicide agents and for erectile dysfunction as secondary to prostate cancer, both under the provisions of the PACT Act. The Veteran's in-service exposure to herbicides is presumed based on his active duty at Udorn Royal Thai Air Force Base in Thailand during the Vietnam era.

The Veteran's prostate cancer is granted service connection due to herbicide agent exposure at Udorn RTAFB. The claims for erectile dysfunction and incontinence are remanded as insufficient medical evidence exists.

The Veteran's claim for service connection for prostate cancer was denied in May 2019. New evidence submitted by the Veteran, including a lay statement describing his in-service exposure to herbicides, has been deemed relevant and sufficient to warrant readjudication of the claim.

The Veteran's prostate cancer is related to his exposure to herbicide agents while stationed at the U-Tapao Royal Thai Air Force Base (RTAFB) in Thailand. The Board has granted service connection for this condition based on presumptive exposure.

The Veteran's initial claim for a compensable rating for prostate cancer residuals from May 14, 2010 to July 10, 2018 was denied. A 10 percent rating is granted starting from July 11, 2018.

The Veteran's prostate cancer is remanded for further development to verify service on USS Kitty Hawk and USS Forrestal within Vietnam waters, verify in-service exposure to herbicide agents, and determine if the condition is related to his service-connected anemia.

The Veteran's prostate cancer was not shown to be related to service, including as due to military environmental exposures. The Board denied the claim for service connection.